Quick Answer
Keros Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $287.42 million for the year ending 2025.
- Keros Therapeutics, Inc. showed a decrease of -48.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $20.75 million | Q2 2019: $15.55 million | Q3 2019: $12.53 million | Q1 2020: $54.52 million | Q2 2020: $144.69 million | Q3 2020: $133.81 million | Q1 2021: $255.20 million | Q2 2021: $237.11 million | Q3 2021: $221.35 million | Q1 2022: $228.59 million | Q2 2022: $215.62 million | Q3 2022: $239.43 million | Q1 2023: $351.43 million | Q2 2023: $322.03 million | Q3 2023: $287.89 million | Q1 2024: $442.44 million | Q2 2024: $405.86 million | Q3 2024: $530.68 million | Q1 2025: $720.54 million | Q2 2025: $690.22 million | Q3 2025: $693.47 million.
- Over the full 7 years of available data (2019 to 2025), Keros Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 3,994.2%.
- Historical annual values: Fiscal year 2025: $287.42 million | Fiscal year 2024: $559.93 million | Fiscal year 2023: $331.15 million | Fiscal year 2022: $279.05 million | Fiscal year 2021: $230.04 million | Fiscal year 2020: $265.88 million | Fiscal year 2019: $7.02 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: